sacituzumab tirumotecan + enfortumab vedotin + pembrolizumab

This combination drug consists of three distinct anticancer agents: - **Sacituzumab tirumotecan** is an antibody-drug conjugate (ADC) targeting TROP2, comprising a TROP2-directed humanized monoclonal antibody linked to a novel belotecan-derived topoisomerase I inhibitor payload via a proprietary linker. It aims to deliver cytotoxic therapy directly to tumor-expressing TROP2 cells, leading to targeted cell death[5][1][3]. - **Enfortumab vedotin** is an ADC targeting Nectin-4, comprising a monoclonal antibody directed against Nectin-4 and conjugated to monomethyl auristatin E (MMAE), a microtubule inhibitor. It delivers MMAE specifically to Nectin-4-positive cancer cells, inducing mitotic arrest and cell death. - **Pembrolizumab** is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by binding to the programmed death receptor-1 (PD-1) on T cells, thus preventing interaction with its ligands PD-L1 and PD-L2. This reactivates T cells to attack tumor cells[4][2][8]. These three drugs together represent a multi-faceted approach: direct cytotoxicity via targeted ADCs and immune system activation via checkpoint blockade. The combination is under clinical evaluation for various advanced/metastatic solid tumors, especially in settings with high unmet need such as triple-negative breast cancer, hormone receptor-positive/HER2- breast cancer, urothelial carcinoma, and non-small cell lung cancer[7][5][1][3].

Other names

sac-TMTEVanti-PD-1 antibodyanti-PD1 antibodyanti-PD 1 antibody